Skip to content

COPD diagnosis, spirometry and case-finding

TL;DR — COPD diagnosis requires a compatible clinical setting and persistent post-bronchodilator airflow obstruction; symptoms or smoking history alone are insufficient (Christenson 2022, PMID 35533707). The fixed FEV1/FVC ratio is simple but can overclassify older adults and underclassify younger adults, so values near 0.70 require clinical and longitudinal interpretation (Haynes 2023, PMID 37353330). Population screening of asymptomatic adults is distinct from targeted case-finding among symptomatic or exposed people. Questionnaires and micro-spirometers can enrich the tested population, but diagnostic spirometry remains necessary (Frith 2020, PMID 31950588). Both underdiagnosis and unsupported diagnostic labels are common worldwide (Ho 2019, PMID 30838057).

Diagnostic construct

COPD is a syndrome rather than a single lesion. Diagnosis joins three domains: chronic respiratory symptoms, relevant exposures or developmental risks, and objectively persistent expiratory airflow obstruction (Christenson 2022, PMID 35533707).

Domain Evidence sought What it cannot establish alone
Symptoms Exertional dyspnea, cough, sputum, wheeze, recurrent “bronchitis” Symptoms are shared by cardiac, airway and systemic disorders
Risk Tobacco, biomass, occupational agents, pollution, early-life injury, asthma Absence of smoking does not exclude COPD (Yang 2022, PMID 35427530)
Physiology Post-bronchodilator FEV1/FVC below threshold Obstruction is not specific to COPD
Imaging Emphysema, gas trapping, airway-wall or vascular abnormalities CT can be abnormal before obstruction and normal in airway-predominant disease (Elbehairy 2024, PMID 38548292)
Course Persistence, exacerbations, decline, treatment response A single encounter cannot define trajectory

Spirometric confirmation

Spirometry measures FEV1, FVC and their ratio before and after a bronchodilator. GOLD operationalizes persistent obstruction as post-bronchodilator FEV1/FVC <0.70 (Vestbo 2013, PMID 22878278). Quality depends on calibration, coaching, maximal inspiration, rapid start, sustained expiration, repeatability and interpretation against appropriate reference values (Haynes 2023, PMID 37353330).

Question Practical interpretation
Why post-bronchodilator? It reduces classification based on reversible narrowing, although reversibility does not cleanly separate asthma from COPD
Fixed ratio or lower limit of normal? Fixed 0.70 is reproducible and guideline-friendly; LLN is age-adjusted but reference-equation dependent
Does FEV1 grade “severity”? It grades airflow limitation, not total disease burden; symptoms, exacerbations, gas exchange and comorbidity remain separate
Is one test enough? Borderline values and tests during instability should be repeated
Can peak flow substitute? No; it cannot reliably quantify FEV1/FVC
Can oscillometry substitute? It may detect small-airway dysfunction, but is not the established diagnostic standard

Age matters because FEV1/FVC falls physiologically. A fixed cutoff can generate false-positive labels in healthy older adults and miss abnormality in younger adults; neither cutoff eliminates clinical misclassification (Haynes 2023, PMID 37353330). The safest interpretation is probabilistic near the boundary and categorical only when physiology and phenotype agree.

Differential diagnosis and coexistence

Alternative or co-condition Clues against uncomplicated COPD Useful adjudication
Asthma Childhood onset, variability, atopy, large treatment-linked variation Serial spirometry, eosinophilic history, treatment response
Heart failure Orthopnea, edema, cardiac signs Natriuretic peptide, ECG, echocardiography
Bronchiectasis Daily purulent sputum, recurrent infection, hemoptysis High-resolution CT
Interstitial lung disease Inspiratory crackles, restriction, low diffusion capacity CT and full pulmonary function tests
Lung cancer Hemoptysis, focal signs, weight loss, new symptom pattern Urgent imaging pathway
Obesity/deconditioning Disproportionate exertional limitation without obstruction Exercise assessment and alternative physiology
Vocal-cord/upper-airway disorder Episodic inspiratory noise or flattening Flow-volume loop and laryngoscopy
Tuberculosis sequelae Prior infection, structural destruction Imaging and microbiological context

Asthma and COPD are not mutually exclusive. A syndromic overlap label should not replace documenting the specific traits that change treatment, such as variable obstruction, eosinophilia, emphysema, chronic infection or smoking exposure (Zeller 2023, PMID 36920815).

Underdiagnosis and overdiagnosis

Underdiagnosis arises when chronic breathlessness is normalized, access to spirometry is poor, or clinicians treat symptoms without objective testing. Overdiagnosis arises when a smoking history, chest radiograph, empiric inhaler response or unverified historical label substitutes for spirometry (Ho 2019, PMID 30838057).

The two errors coexist rather than cancel each other. A health system can miss physiologically affected people while prescribing long-term inhalers to people without persistent obstruction. Consequences include delayed risk reduction in the former group and adverse effects, cost and diagnostic anchoring in the latter (Ho 2019, PMID 30838057).

Screening versus case-finding

Strategy Population Test sequence Evidence position
Population screening Asymptomatic general population Invitation → spirometry Benefit on long-term outcomes remains unproved
Opportunistic case-finding Symptomatic or exposed attendees Questions/micro-spirometry → diagnostic spirometry Increases diagnostic yield (Haroon 2015, PMID 26313400)
Active case-finding Registry or community risk selection Algorithm → confirmatory testing Feasibility established; outcome benefit less certain (Preteroti 2020, PMID 32299864)
Practice-nurse pathway Primary-care attendees Structured history → spirometry Feasible in primary care with training (Bunker 2009, PMID 19893824)

A systematic review found targeted case-finding strategies identify previously undiagnosed COPD, but heterogeneity in questionnaires, thresholds and follow-up limits comparison (Haroon 2015, PMID 26313400). Micro-spirometry and questionnaires are triage tools: their role is to reduce full-spirometry burden, not confer the diagnosis (Frith 2020, PMID 31950588).

The RADICALS trial compared case-finding approaches in primary care and illustrates the operational issue: yield depends on whom the system contacts, what prescreen is used, and whether positive screens reach quality-assured spirometry (Alotaibi 2023, PMID 37492489).

Early states and diagnostic boundaries

“Pre-COPD,” preserved-ratio impaired spirometry (PRISm), young COPD and CT-defined disease describe risk states, not interchangeable diagnoses. Some people have symptoms, emphysema or accelerated decline before crossing an obstruction threshold; others with PRISm remain stable or transition between categories (Li 2025, PMID 40624819).

State Working description Main uncertainty
Pre-COPD Symptoms or structural/functional abnormality without obstruction Which definition predicts preventable progression?
PRISm Reduced FEV1 with preserved FEV1/FVC Heterogeneous causes and variable transitions
Young COPD Obstruction in early adulthood Developmental versus exposure-driven trajectories
Mild airflow limitation Obstruction with relatively preserved FEV1 Who benefits from pharmacotherapy beyond risk reduction?
CT emphysema without obstruction Structural destruction before spirometric threshold Whether treatment changes outcomes

These labels are useful research strata but risk medicalizing nonspecific symptoms. Their value depends on demonstrating incremental prognosis and an intervention that changes that prognosis (Li 2025, PMID 40624819).

A quality-assured diagnostic pathway

  1. Document symptoms, time course, functional impact and exacerbation-like events.
  2. Quantify tobacco, household, occupational and ambient exposures.
  3. Examine for respiratory and cardiac alternatives.
  4. Perform pre/post-bronchodilator spirometry to technical standards.
  5. Repeat borderline or unstable measurements.
  6. Reconcile discordance among symptoms, obstruction and imaging.
  7. Investigate red flags and phenotype-specific questions rather than ordering a universal panel.
  8. Record diagnostic confidence and the traits that drive treatment.

Primary-care spirometry can be reliable when equipment, training, feedback and referral pathways are maintained; merely placing a spirometer in a practice is insufficient (Derom 2008, PMID 18166597). Historical evidence reviews similarly separated the accuracy of spirometry from proof that broad screening improves patient outcomes (Wilt 2005, PMID 16238364).

Research implications

Diagnostic studies should report the reference equation, bronchodilator protocol, fixed-ratio and LLN results, test quality, symptom selection and prior treatment. Case-finding trials should measure not only diagnoses made but sustained smoking cessation, appropriate treatment changes, exacerbations, health status, harms and cost.

The central unresolved issue is not whether spirometry detects obstruction; it is whether selecting and acting on earlier abnormalities changes a patient-important trajectory (Sims 2012, PMID 22610368; Li 2025, PMID 40624819).

Quantified boundary problems

Boundary Evidence Practical implication
Fixed ratio versus LLN In 1,328 asymptomatic healthy never-smokers aged 56–84, the two rules produced significantly different obstruction counts in both sexes; the fixed 0.70 rule likely overdiagnosed older adults (Wang 2013, PMID 24034095). Report both values near the boundary and interpret age, symptoms and exposure rather than treating 0.699 as categorical truth.
Population screening versus case-finding The USPSTF's 2022 reaffirmation concluded with moderate certainty that screening asymptomatic adults has no net benefit and retained a D recommendation (USPSTF 2022, PMID 35536260). This does not answer whether targeted testing of symptomatic or exposed people improves outcomes.
Low early-adult lung function COPD developed in 26% of people with FEV1 <80% predicted before age 40 versus 7% with preserved early FEV1 over 22 years (Lange 2015, PMID 26154786). A single late-life ratio cannot reconstruct the causal trajectory.
Prognosis within the same label COPD arising after normal attained FEV1 had higher all-cause mortality than COPD arising from low attained FEV1 (HR 1.93, 95% CI 1.14–3.26) (Marott 2020, PMID 32289231). “COPD” contains prognostically distinct routes after obstruction is established.
Structural pre-COPD Terminal bronchiole narrowing and loss preceded emphysematous destruction in explanted-lung micro-CT (McDonough 2011, PMID 22029978). Normal conventional spirometry does not exclude biologically important early disease.
Imaging phenotype CT/MRI can quantify emphysema, airway wall, gas trapping, ventilation and perfusion, but no imaging abnormality alone replaces post-bronchodilator obstruction for conventional diagnosis (Elbehairy 2024, PMID 38548292). Imaging should explain discordance, not silently redefine the case.

Competing diagnostic positions

Position Strength Main objection
Fixed post-bronchodilator FEV1/FVC <0.70 Simple and embedded in trials/guidelines (Vestbo 2013, PMID 22878278) Age-related false positives and threshold instability (Wang 2013, PMID 24034095)
LLN/z-score obstruction Adjusts for age, sex and height Reference-equation dependence and less linkage to legacy trial eligibility
Symptom/exposure-enriched case-finding Higher yield than untargeted testing (Haroon 2015, PMID 26313400) Yield is not evidence of improved long-term outcomes
Broad “pre-COPD” construct Captures CT, symptoms and trajectory before fixed obstruction (Li 2025, PMID 40624819) Risks medicalizing heterogeneous abnormalities without proven intervention

Future diagnostic studies should report bronchodilator protocol, reference equation, fixed-ratio and LLN results, repeatability, symptoms, exposure, prior asthma, CT availability, treatment changes and patient-important outcomes. BOLD’s 9,425-person standardized post-bronchodilator design shows why method consistency matters across sites (Buist 2007, PMID 17765523), while COPDGene illustrates the value—and selection limits—of pairing spirometry with deep phenotyping (Regan 2010, PMID 20214461).

Oscillometry: useful adjunct, unproved replacement

In 117 people suspected of COPD, oscillometric measures produced areas under the ROC curve of 0.80–0.84; an AX threshold of 8.66 cmH2O/L had 79.1% sensitivity and 78.0% specificity against spirometric diagnosis (Chaiwong 2020, PMID 33121279). A separate 115-person retrospective study found BMI-adjusted airway resistance predicted more advanced obstruction with AUC 0.782 (95% CI 0.620–0.945), while also showing that obesity changed the useful cutoff (Chen 2024, PMID 38187302). Against CT-confirmed emphysema in 88 clinic patients, an oscillometry model had cross-validated AUC 0.839 and NPV 93.7%, but PPV only 55.2% (Klitgaard 2023, PMID 36836082). These small, selected cross-sectional studies support a low-effort rule-out or phenotyping role; they do not establish oscillometry as a substitute for quality-assured post-bronchodilator spirometry.

Broadband 3D oscillometry in 107 COPD cases and 61 controls produced AUCs from 0.766 to 0.910 across resistance/reactance parameters, but correlations with spirometry were only moderate (strongest r −0.467), reinforcing that the tests measure overlapping rather than identical constructs (Tang 2021, PMID 33574662). CT total-airway count supplies another non-spirometric signal: in 1,184 CanCOLD participants it was 19% lower in GOLD I/II than never-smokers after adjustment for emphysema and independently predicted six-year FEV1 and FEV1/FVC decline (Kirby 2018, PMID 28886252). Neither modality yet has a proven treatment-trigger threshold.

Outcome validation does not eliminate threshold error

Across 24,207 adults followed for a median 15 years, 3,925 COPD hospitalizations or COPD-related deaths occurred over 340,757 person-years. The outcome-optimized FEV1/FVC threshold was 0.71 (C statistic 0.696), statistically indistinguishable from 0.70 (difference 0.001, 95% CI −0.002 to 0.004) and more discriminative than LLN in that pooled analysis (difference 0.034, 95% CI 0.028–0.041) (Bhatt 2019, PMID 31237643). This supports 0.70 as a population risk separator but does not show that every person just below it has COPD or should be treated.

The randomized early-diagnosis pathway reduced respiratory health-care encounters (incidence-rate ratio 0.48, 95% CI 0.36–0.63), but enrolled symptomatic people with newly confirmed asthma or COPD and bundled diagnosis with specialist and educator management (Aaron 2024, PMID 38767248). It therefore answers a narrower and more actionable question than asymptomatic population screening while leaving the COPD-specific contribution uncertain.

Open questions

  • Which repeat-testing rule best distinguishes persistent disease from threshold noise near FEV1/FVC 0.70? (Haynes 2023, PMID 37353330)
  • Does targeted case-finding reduce exacerbations, disability or mortality rather than only increase diagnostic yield? (Haroon 2015, PMID 26313400)
  • Which pre-COPD or PRISm subgroup has a modifiable natural history? (Li 2025, PMID 40624819)
  • Can quality-assured home spirometry improve access without increasing false labels? (Frith 2020, PMID 31950588)
  • How should asthma traits be represented without using an imprecise overlap category? (Zeller 2023, PMID 36920815)

References

  1. Christenson SA, et al. Chronic obstructive pulmonary disease. Lancet. 2022. PMID 35533707
  2. Ho T, et al. Under- and over-diagnosis of COPD: a global perspective. Breathe (Sheff). 2019. PMID 30838057
  3. Haynes JM. The role of pulmonary function testing in the diagnosis and management of COPD. Respir Care. 2023. PMID 37353330
  4. Vestbo J, et al. Global strategy for the diagnosis, management, and prevention of COPD: GOLD executive summary. Am J Respir Crit Care Med. 2013. PMID 22878278
  5. Frith PA, et al. Detecting COPD using micro-spirometry and/or questionnaire. Respirology. 2020. PMID 31950588
  6. Haroon SM, et al. Effectiveness of case finding strategies for COPD in primary care: a systematic review and meta-analysis. NPJ Prim Care Respir Med. 2015. PMID 26313400
  7. Preteroti M, et al. Population-based case-finding to identify subjects with undiagnosed asthma or COPD. Eur Respir J. 2020. PMID 32299864
  8. Alotaibi N, et al. Different case finding approaches to optimise COPD diagnosis: evidence from the RADICALS trial. Int J Chron Obstruct Pulmon Dis. 2023. PMID 37492489
  9. Derom E, et al. Primary care spirometry. Eur Respir J. 2008. PMID 18166597
  10. Wilt TJ, et al. Use of spirometry for case finding, diagnosis, and management of COPD. Evid Rep Technol Assess (Summ). 2005. PMID 16238364
  11. Sims EJ, et al. Spirometry: an essential tool for screening, case-finding, and diagnosis of COPD. Prim Care Respir J. 2012. PMID 22610368
  12. Zeller TA, et al. Distinguishing asthma and COPD in primary care: a case-based approach. Am Fam Physician. 2023. PMID 36920815
  13. Li Y, et al. Research progress in early states of COPD. Expert Rev Respir Med. 2025. PMID 40624819
  14. Yang IA, et al. COPD in never-smokers. Lancet Respir Med. 2022. PMID 35427530
  15. Elbehairy AF, et al. Advances in COPD imaging using CT and MRI. Eur Respir J. 2024. PMID 38548292
  16. Wang Y, et al. Lower limit of normal and airflow-limitation misclassification. Chin Med J (Engl). 2013. PMID 24034095
  17. US Preventive Services Task Force. Screening for COPD: reaffirmation recommendation statement. JAMA. 2022. PMID 35536260
  18. Lange P, et al. Lung-function trajectories leading to COPD. N Engl J Med. 2015. PMID 26154786
  19. Marott JL, et al. Lung-function trajectories as predictors of exacerbations and mortality. Am J Respir Crit Care Med. 2020. PMID 32289231
  20. McDonough JE, et al. Small-airway obstruction and emphysema in COPD. N Engl J Med. 2011. PMID 22029978
  21. Buist AS, et al. International variation in COPD prevalence: the BOLD Study. Lancet. 2007. PMID 17765523
  22. Regan EA, et al. COPDGene study design. COPD. 2010. PMID 20214461
  23. Bunker J, et al. Feasibility and efficacy of COPD case finding by practice nurses. Aust Fam Physician. 2009. PMID 19893824
  24. Chaiwong W, et al. Diagnostic ability of impulse oscillometry in diagnosis of COPD. COPD. 2020. PMID 33121279
  25. Chen KY, et al. Impulse oscillometry and its independent role in the diagnosis of COPD. Heliyon. 2024. PMID 38187302
  26. Klitgaard A, et al. Impulse oscillometry as a diagnostic test for pulmonary emphysema in a clinical setting. J Clin Med. 2023. PMID 36836082
  27. Tang Z, et al. Application value of broadband three-dimensional impulse oscillometry in COPD. Int J Chron Obstruct Pulmon Dis. 2021. PMID 33574662
  28. Kirby M, et al. Total airway count on CT and risk of COPD progression. Am J Respir Crit Care Med. 2018. PMID 28886252
  29. Bhatt SP, et al. Discriminative accuracy of FEV1:FVC thresholds for COPD-related hospitalization and mortality. JAMA. 2019. PMID 31237643
  30. Aaron SD, et al. Early diagnosis and treatment of COPD and asthma: a randomized, controlled trial. N Engl J Med. 2024. PMID 38767248